Lexaria Bioscience Corp.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
52886N307
SEDOL
N/A
CIK
N/A
lexariabioscience.com
LEI:
FIGI: BBG00JQ5B1M9
LEXX
Lexaria Bioscience Corp.
GICS: - · Sector: - · Sub-Sector: -
NAME
Lexaria Bioscience Corp.
ISIN
US52886N3070
TICKER
LEXX
MIC
REUTERS
LEXX.OQ
BLOOMBERG
LEXX US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants

The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by AccessWire.

Wed, 09.10.2024       Lexaria Bioscience
US52886N3070

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / October 9, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has begun, for human pilot s...
Read More
Lexaria Bioscience
Technical Analysis Termsheet Terminal
Permalink
Tue, 08.10.2024       Lexaria Bioscience
US52886N3070

KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on recent glucagon-like peptide-1 ("GLP-1") receptor agonist market sector advancements.In 2020 the total market size ...
Read More
Lexaria Bioscience
Technical Analysis Termsheet Terminal
Permalink
Tue, 01.10.2024       Lexaria Bioscience
US52886N3070

KELOWNA, BC / ACCESSWIRE / October 1, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Michael Shankman, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership t...
Read More
Lexaria Bioscience
Technical Analysis Termsheet Terminal
Permalink
Fri, 27.09.2024       Lexaria Bioscience
US52886N3070

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE / September 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that approval has been re...
Read More
Lexaria Bioscience
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements